Trial Profile
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 According to a MediciNova media release, the company look forward to future discussions with Dr. Ray on further analyses, including subgroup analyses, and the future direction of MN-166 and AUD.
- 29 Jun 2023 According to a MediciNova media release, results from this trial were presented at the 46th Annual Research Society on Alcoholism (RSA) Scientific Meeting 2023.